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The 11p15.5 region harbors three imprinted sense/antisense transcript pairs, SLC22A18/SLC22A18AS, IGF2/IGF2AS (PEG8), and KCNQ1/
KCNQ1OT1 (LIT1). SLC22A18 (solute carrier family 22 (organic cation transporter) member 18) and its antisense transcript SLC22A18AS are
paternally suppressed in fetal samples. In adult tissue, SLC22A18 displays polymorphic imprinting, but the imprinting status of SLC22A18AS
remains elusive. SLC22AI8 DNA-PCR–RFLP analysis using NlaIII restriction digestion identified SLC22A18 heterozygotes within this breast
tissue cohort (n = 89). Commercial sequencing identified informative SLC22A18AS samples. Random hexamer-primed cDNA synthesis,
SLC22A18/SLC22A18AS-specific PCR, and imprinting evaluation by commercial sequencing demonstrated that SLC22A18AS displays a
nonimprinted profile in reduction mastectomies (n = 6). However, SLC22A18 showed a gain of imprinting (GOI) in 1/4 of these normal cases. In
the malignant cohort, GOI was also demonstrated in 18% for SLC22A18 and 14% for SLC22A18AS, occurring concomitantly in one case. This
study reports the imprinting status of SLC22A18AS in adult tissue, and shows that GOI affects both the sense, and antisense transcripts at this
locus in human breast tissue.
© 2006 Elsevier Inc. All rights reserved.Keywords: SLC22A18; SLC22A18AS; 11p15.5; Breast cancer; Gain of imprinting; Loss of heterozygosity; Natural antisense transcript; Imprinted genesNatural antisense transcripts (NATs) have been implicated
in many aspects of eukaryotic gene expression, including
genomic imprinting. To date, approximately 2500 mammalian
NATs have been found, indicating that antisense transcription
might be a common mechanism in the regulation of gene
expression in human cells. Moreover, they may play a pivotal
role in a variety of human diseases, as is the case for the
imprinted UBE3A sense/antisense pair located in the
imprinted cluster 15q11–15q13, which is associated with
the Prader–Willi and Angelman syndromes [1].
The 11p15.5 region is one of the largest imprinting clusters in
the human genome, and contains multiple imprinted genes, the
majority of which demonstrate predominant or complete
maternal expression. This region is frequently altered in⁎ Corresponding author. Fax: +353 1 7166888.
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doi:10.1016/j.ygeno.2006.02.004neoplasia associated with the neonatal overgrowth syndrome
Beckwith–Wiedemann syndrome (BWS) and with a variety of
sporadic cancers [2]. The importance of a maternally active
locus at chromosome 11p15 in tumorigenesis is supported by the
finding that loss of heterozygosity (LOH) at chromosome 11p15
in sporadic Wilms' tumors specifically involves maternal alleles
[2]. The inherent influence of NATs within the 11p15.5 region is
suggested by the fact that it harbors three imprinted sense/
antisense transcript pairs, IGF2/IGF2AS (PEG8), KCNQ1/
KCNQ1OT1 (LIT1), and SLC22A18/SLC22A18AS (http://
www.geneimprint.com).
SLC22A18 (solute carrier family 22 (organic cation
transporter) member 18) (http://www.gene.ucl.ac.uk/) is located
within the 11p15.5 cluster, and has been assigned a number of
different nomenclatures [3–7]. Blast homology analysis
suggests that SLC22A18 is a member of a family of
polyspecific transporters and multidrug resistance genes [6].
Table 1
Frequency of heterozygosity and gain of imprinting (GOI) of SLC22A18 and
SLC22A18AS
Cohort SLC22A18 SLC22A18AS




12 8 2 2 1 13 6 1 6 2
Infiltrating
lobular








3 1 – 2 – 3 2 1 – –
Mixed
histologies
5 4 – 1 – 7 3 – 4 –




5 5 – – – 5 3 – 2 –
Total
malignant
57 43 3 11 2 a 58 29
8
21 3 b
% 76% 5% 19% 18% 50% 14% 36% 14%
Benign
Fibroadenomas 3 2 1 – – 3 – – 3 1
(33%)
Fibrocystic 3 1 2 – – 3 2 1 – –
Reductions 17 12 1 4 1 16 7 – 9 c –
Total benign 23 15 4 4 1 d 22 9 1 12 1 e
% 66% 17% 17% 25% 41% 5% 54% 8%
a Cases 12T and 85T (Fig. 1E).
b Cases 8T, 43T, and 85T (Fig. 2A).
c Only 6 available for imprinting analysis (Fig. 2B).
d Case 30RM (Fig. 1E).
e Case 142FA.
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RING105 [8]. Structural mutations in SLC22A18 are rare, with
isolated reports of point mutations in a breast cancer cell line, a
rhabdomyosarcoma cell line [6], and Wilms' and lung tumors
[4]. Exonic deletions in Wilms' tumors [4] and LOH in
hepatoblastomas [9] have also been reported, indicating that
SLC22A18 may play a role in tumorigenesis. As these structural
changes are rare, the possibility arises that alterations in the
epigenetic/imprinting mechanisms may contribute to tumori-
genesis [6]. This is highlighted by the reduction of SLC22A18
expression in the absence of LOH at 11p15.5 in hepatoblasto-
mas [9].
Although maternally expressed in fetal tissue (http://www.
IGC.otago.ac.nz/home.html), information on the imprinting
phenotype of SLC22A18 in adult tissue is limited [4].
Abnormalities in the imprinting pattern of SLC22A18 in the
11p15.5 region have been identified in a number of sporadic
tumors, including hepatocellular carcinomas, Wilms' tumors,
and BWS-associated malignancies [10], for example embryonic
tumors [11]. The most frequent abnormality in hepatocellular
carcinomas is gain of imprinting (GOI), which has been shown
to result in a concomitant reduction of expression of SLC22A18
and other genes in this region [2].
SLC22A18 has an associated NAT, denoted SLC22A18AS
(solute carrier family 22 (organic cation transporter), member
18 antisense) (http://www.gene.ucl.ac.uk/), which has also been
described independently in the literature [6,7,12]. The
SLC22A18 and SLC22A18AS genes overlap in their 5′ regions
in divergent orientations, with the first exon of SLC22A18AS
sharing 31 bp with the second exon of SLC22A18. There have
been few studies examining SLC22A18AS, with no disease-
associated mutations found to date [7]. Information on its
imprinting phenotype is limited to fetal tissue, with 2/17
informative fetal samples displaying a monoallelic pattern in all
five tissues tested [12]. Currently, the imprinting status of
SLC22A18AS in adult tissue is unknown.
This study reports the imprinting status of the
SLC22A18AS gene in adult tissue, and shows that the
phenomenon of GOI affects both the sense and the antisense
transcripts at this locus.
Results
Identification of informative cases for SLC22A18 and
SLC22A18AS
Eighty-nine breast tissue samples, including 23 benign cases
(17 reduction mastectomy (RM) cases, 3 fibroadenomas (FA),
and 3 with fibrocystic change (FC)), 61 malignant tumors (T)
(56 primary and 5 secondary), and 5 paired tumor-associated
normal (TAN) cases, were screened to identify informative
cases for both SLC22A18 and SLC22A18AS.
SLC22A18
Using a previous methodology [4], heterozygosity for
SLC22A18 was demonstrated in 11/57 (19%) of themalignant breast lesions and 4/23 (17%) of benign tissues
(Table 1). Cases 12T and 13T are examples of informative
cases, with case 14T demonstrating allele g (Fig. 1B). All
other cases are informative for the c allele (Fig. 1B). A
higher proportion of samples were uninformative for allele c
compared to allele g in both the malignant (76% vs 5%)
and the nonmalignant cohorts (66% vs 17%) (Table 1). In
two informative paired samples, 135T/135TAN and 138T/
138TAN, LOH was demonstrated for SLC22A18 in the
former pair, with structural loss of allele g (Fig. 1C).
Additional sequencing data demonstrated clear evidence of
loss of the g nucleotide (Fig. 1D).
SLC22A18AS
Using novel primers to a published single nucleotide
polymorphism (SNP) [13], heterozygosity for SLC22A18AS
was demonstrated in 21/58 (36%) of malignant breast lesions
and 12/22 (54%) of benign tissues (Table 1). Examples of
heterozygous profiles are shown in Fig. 2A (43T, 85T, 85T,
and 20T). Moreover, there was a higher proportion of samples
demonstrating allele a compared to allele g in both the
14 E. Gallagher et al. / Genomics 88 (2006) 12–17malignant (50% vs 14%) and the benign tissue cohort (41%
vs 5%) (Table 1). The informative pair (126T/126TAN) did
not display LOH at this locus.
Imprinting phenotypes of SLC22A18 and SLC22A18AS
Normal tissue (reduction mastectomy tissue)
In the current study, 1/4 of the informative normal
reduction mastectomies demonstrated monoallelic expression
for SLC22A18 (case 30RM) (Fig. 1E). In the literature theimprinting status of SLC22A18AS has not been determined.
Of the nine informative reduction mastectomy samples, six
were available for imprinting analysis. Biallelic expression
of SLC22A18AS was seen in all these cases (Fig. 2B), with
three displaying allelic equality (cases 36RM, 3RM, and
7RM) (Fig. 2B). This indicates a nonimprinted profile for
SLC22A18AS in normal adult breast tissue. Case 13RM
was informative at both loci, and biallelic expression was
retained.
Malignant tissue
The phenomenon of GOI affected both loci within the
malignant breast cohort. SLC22A18 GOI was seen in 2/11
cases (18%) (case 12T and case 85T) (Table 1; Fig. 1E) and
SLC22A18AS GOI was seen in 3/21 (14%) (cases 8T, 43T, and
85T) (Fig. 2A) and 1/3 informative fibroadenomas (case
142FA) (Table 1). Sample 12T, which showed a gain of
imprinting for SLC22A18, was unaltered at the SLC22A18AS
locus. Case 85T, which displayed GOI at both loci, also
showed a loss of imprinting of IGF2 (data not shown). Sample
8T, which was uninformative for SLC22A18 and showed a
gain of imprinting for SLC22A18AS, also showed a loss of
imprinting for IGF2 (data not shown). Case 13T, although
informative for SLC22A18 (Fig. 1B), demonstrated biallelic
expression (Fig. 1E).
Of the informative pairs with retained heterozygosity
(SLC22A18 pair 138T/138TAN and SLC22A18AS pairFig. 1. Heterozygosity and imprinting analysis of SLC22A18. (A) Schematic
representation showing the position of the NlaIII RFLP, site, and resultant
polymorphic fragments, post-NlaIII digestion. Allele c is represented by a
fragment at 189 bp, allele g by fragments at 112 and 77 bp, and a heterozygous
profile by all three fragments. A common fragment (87 bp) is seen in all cases,
due to the presence of a nonpolymorphic CATG NlaIII restriction site. (B)
Heterozygosity profiling of SLC22A18. SLC22A18 NlaIII restriction digestion
profiles following electrophoretic separation through 6% PAGE. Samples 12T
and 13T display a heterozygous profile with polymorphic fragments present at
189 bp (allele c) and 112 bp/77 bp (allele g), with the common fragment shown
at 87 bp. Cases 15T, 17T, 18T, 19T, 20T, 21T, and 26T display allele c (189 bp),
with sample 14T displaying the g allele (112/77). (C) NlaIII restriction digestion
profiling of SLC22A18 in paired normal (TAN) and corresponding tumor (T)
samples. Demonstration of loss of heterozygosity (LOH) of SLC22A18 in one
of two paired tumor and normal cases. Case 138T represents a primary tumor
with matched TAN (normal tissue excised from a site close to the malignant
lesion), while case 135T is a recurrent tumor with a corresponding TAN. LOH in
the latter is clearly evident with the loss of allele g. (D) DNA sequence analysis
of loss of heterozygosity of SLC22A18. Loss of heterozygosity, in one of two
paired tumor and normal cases from panel C, using direct sequence analysis
following DNA-PCR. A LOH profile is seen in case 135T, which displays only
one peak/allele at the highlighted polymorphic site, while its corresponding
normal (135TAN) shows a biallelic profile. Paired sample 138T/138TAN shows
a biallelic profile in both, thereby confirming the lack of LOH in this case. (E)
Analysis of the altered imprinting status of SLC22A18. Demonstration of gain
of imprinting (GOI) of SLC22A18, using direct sequence analysis following RT-
PCR. A GOI profile is seen in cases 12T, 85T, and 30RM (top row from left to
right), which display only one peak/allele at the highlighted polymorphic site,
while case 13T and the paired sample 138T and 138TAN (bottom from left to
right) show an unaltered biallelic profile. The clear heterozygous profiles of
cases 12T and 13T are shown in panel B, and those of 138T and 138TAN are
shown in panels C and D.
Fig. 2. Heterozygosity and imprinting analysis of SLC22A18AS. (A) Sequence
analysis of the altered imprinting status of SLC22A18AS. Cases 43T, 85T, 8T,
and 20T are all heterozygous at the DNA level as shown by the presence of two
peaks/alleles at the highlighted polymorphic site. Cases 43T, 85T, and 8T
demonstrate GOI, shown by the absence of one of the alleles in the
corresponding chromatograms. In contrast, case 20T retains both alleles. (B)
The imprinting status of SLC22A18AS in six informative normal tissues derived
from reduction mastectomies. All display a biallelic profile.
15E. Gallagher et al. / Genomics 88 (2006) 12–17126T/126TAN), biallelic expression was seen in all four
samples.
Discussion
In the current study the restriction fragment length
polymorphism (RFLP) and SNP used for both SLC22A18
and SLC22A18AS occurred at a frequency similar to that
previously described [4,13]. For SLC22A18, of two
informative pairs one case (135T/TAN) displayed a LOH
at the SLC22A18 locus. This finding corroborates previous
data showing that SLC22A18 was affected by LOH in
hepatoblastomas [9]. This is in contrast to data of a series of
paired hepatocellular carcinomas that were not affected by
LOH at this locus [2].The imprinting phenotype of SLC22A18 has been shown to
exhibit tissue-specific and developmentally specific paternal
imprinting, but the stringency of allele-specific expression is not
absolute [14]. Within our cohort, polymorphic imprinting is
evident within both malignant and normal tissue, as evidenced
by both monoallelic and biallelic expression patterns for
SLC22A18. Gain of imprinting of SLC22A18AS was found
in 3/21 (14%) of malignant cases and 1/3 (33%) of informative
fibroadenomas. SLC22A18 GOI was also found in 2/11 (18%)
of malignant cases and 1/4 (25%) of reduction mastectomies
showing a similar monoallelic profile. This allelic transcrip-
tional repression is similar to published data, in which 4/27
(15%) displayed a gain of imprinting at the SLC22A18 locus
[6]. The finding of GOI in the nonmalignant presentations raises
the possibility that gain of imprinting may be an early event in
tumorigenesis.
The analysis of the imprinting status of SLC22A18AS within
six informative reduction mastectomy samples demonstrated
biallelic expression. This suggests that SLC22A18AS displays
a nonimprinted profile in normal breast tissue. GOI of
SLC22A18AS was found in 3/21 (14%) of malignant cases
and 1/3 (33%) of informative fibroadenomas. The discovery of
GOI in the antisense SLC22A18AS locus in this study is a novel
finding. Determining the parental origin of the allele undergoing
GOI for both SLC22A18 and SLC22A18AS was not possible
due to the unavailability of parental DNA.
The role SLC22A18 plays in tumorigenesis is functionally
unclear. Our own data have suggested that SLC22A18 is
regulated epigenetically through a GOI phenomenon. Loss of
heterozygosity in this 11p15.5 domain has been detected in a
wide variety of tumors [15–18], and suggests the presence of a
number of tumor suppressor genes within this region. The
finding of LOH in our cohort supports its possible role as a
tumor suppressor gene [2]. This is highlighted by the recent
finding that SLC22A18 is a substrate for the novel ubiquitin
ligase RING105, involved in cell cycle regulation. Reduction in
the availability of SLC22A18 through GOI or LOH may
therefore compromise the efficiency of RING105 to arrest the
cell cycle at the G1/S transition, fueling the potential for
abnormal cell proliferation in cancer [8].Materials and methods
Patient samples
Fresh human breast tumor surgical specimens were collected prospec-
tively in the Mater Misericordiae and Mater Private Hospitals (Dublin,
Ireland) between 2001 and 2004. The cases in this study represent a
randomly selected cohort collected over this period. Ethical approval was
obtained for the study through the Mater Hospital ethics committee, and all
patients signed a consent form allowing use of their tissue. Tumor samples
were taken from mastectomy or wide local excision surgical specimens under
the supervision of a pathologist. Fresh tissue samples were snap frozen and
stored at −70°C. Prior to nucleic acid extraction, separate samples from each
specimen were set aside for the purpose of DNA and RNA extraction. One
piece was also set aside for fixing and paraffin embedding to allow
hematoxylin and eosin-stained histopathological examination. The cohort
consisted of 89 breast tissue samples, including 23 benign (17 RM cases, 3
FA, and 3 with FC) and 61 (56 primary and 5 secondary) malignant cases,
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infiltrating lobular carcinomas, 29 infiltrating ductal and DCIS component, 3
infiltrating lobular carcinomas and LCIS component, 7 mixed infiltrating
lobular and infiltrating ductal carcinomas, and 2 others (colloid carcinoma
and an intracystic papillary carcinoma). TAN tissue (tissue excised from a
region close to the tumor site) was available on 5 malignant cases (4 primary
and 1 secondary).
Identification of informative cases for SLC22A18 and SLC22A18AS
SLC22A18
DNA-PCRs were performed on 0.25 μg of genomic DNAwith Promega Taq
DNA polymerase using a novel forward primer, 10aNEW, 5′-TTCAGCA-
GGGACAGCAGTCAGG-3′ and a previously published reverse primer, 10b, 5′-
ACCGGGTAGCTCCTAGGGCTTCCTGGA-3′ [4]. These primers flank a tran-
scribable polymorphic site within exon 10 (G1166/C1166) [4] (rs:3177634)
(http://www.ncbi.nlm.nih.gov/SNP/index/html). This transversion from C to G
creates an NlaIII RFLP (CATG). The cycling conditions consisted of an initial
95°C for 5 min, followed by 40 cycles of 95°C for 45 s, 60°C for 30 s, and 72°C
for 90 s with a final extension at 72°C for 10 min. The resultant 284-bp product
was digested with NlaIII and electrophoresed through 6% PAGE gels and
stained with ethidium bromide. The tissue samples yielding polymorphic
bands of 189 (allele c) and the doublet 112 and 77 bp (allele g) indicated
heterozygosity. For sequencing the resultant 284-bp product was purified using a
Concert rapid PCR purification, with commercial sequencing (MWG Biotech)
to identify the presence/loss of the c and g alleles.
SLC22A18AS
DNA-PCRswere carried out on 0.25μg of genomicDNAwithQiagenHotStar
Taq polymerase using a novel forward primer, ORCF, 5′-GCTGGGTGA-
AGAAGAAAGCA-3′ and reverse primer, ORCR, 5′-TGCCTTTAAGAC-
TGGCTGAG-3′, which flank a transcribable A266G base substitution
polymorphism [13] (rs:365605) (http://www.ncbi.nlm.nih.gov/SNP/index/
html). The cycling conditions consisted of an initial 95°C for 15 min, followed
by 35 cycles of 95°C for 20 s, 57°C for 20 s, and 72°C for 30 s and a final
extension of 72°C for 5 min. The resultant 259-bp product was purified using a
Concert rapid PCR purification, with commercial sequencing (MWGBiotech) to
identify the presence of the a and g alleles.
Analysis of altered imprinting status of SLC22A18 and SLC22A18AS
Total RNA was extracted from informative/heterozygous cases using the
guanidine-based TRIzol reagent, according to the manufacturer's instructions.
All RNA samples were DNase treated before cDNA synthesis. Random
hexamer cDNA was synthesized from 1 μg of total RNA using the standard
Superscript II Kit. The cDNA was subsequently used as template for gene-
specific reverse transcription PCR (RT-PCR). RT-PCR was performed on 1 μl of
first-strand cDNA with Qiagen HotStar Taq polymerase.
SLC22A18 (GenBank Accession No. AF059663)
Using a novel forward primer, 64, 5′-AGCTGAGCAGCCACTTCTC-3′
and a novel reverse primer, 329, 5′-AAAGCTGCGGTACAGGAGG-3′, the
cycling conditions consisted of an initial 95°C for 15 min, followed by 40 cycles
of 95°C for 1 min, 60°C for 1 min, and 72°C for 2 min and a final extension at
72°C for 10 min. Intron-spanning primers were used to generate a 284-bp RT-
PCR product, the forward primer (64) was located in exon 9, starting at
nucleotide position 1084 and finishing at nucleotide position 1102, and the
reverse primer (329) was located in exon 11, starting at nucleotide position 1349
and finishing at nucleotide 1367. The spanned introns were 232 and 2453 bp in
length, further emphasizing the specificity of these primers for the cDNA of
SLC22A18. The resultant 284-bp product of identified heterozygotes was
prepared for commercial sequencing by MWG Biotech using the Concert rapid
PCR purification system to determine the imprinting phenotype and the
incidence of altered imprinting.
SLC22A18AS (GenBank Accession No. NM_007105)
ORCF and ORCR primers were also used to generate the SLC22A18AS
expression products, which were subsequently prepared as previouslydescribed for commercial sequencing by MWG Biotech using the Concert
rapid PCR purification system. The ORCR primer was also intron spanning,
with the first 17 bp located in exon 3 starting at position 788 bp and the
last 3 bp in exon 4 finishing at 807 bp. The spanned intron was 10,760 bp
in length, further emphasizing the specificity of these primers for the cDNA
of SLC22A18AS.
The second exon of SLC22A18 shares 31 bp with the first exon of its
antisense transcript SLC22A18AS [7], therefore all the primers designed for
this study lay outside this overlapping region. GOI in this study was taken
as complete allelic repression or an allelic imbalance of greater or equal to
4:1 and describes a change from a biallelic to a monoallelic expression
profile.
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